Obesity

52 trials 10 recruiting MedDRA PT
52 Registered trials
10 Recruiting
23 Unique sponsors
23 Unique IMPs
44 Commercial trials
Drug classes (ATC)
ATC code not specified 41
A Gastroenterology (ATC A) 10
B Haematology (ATC B) 2
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 20 substances
GLP-1 receptor agonist 2 substances
Antiplatelet / NSAID 1 substance
Phase III: 20 Phase II: 5 Phase I/II: 1 Phase IV: 3 Phase I: 3 Phase I (Other): 19 Other: 1

Filter these 52 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 52 trials

Phase III

20 trials
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2024-515523-11-00 6 countries 2025 n=420
    Ended
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2024-515524-36-00 8 countries 2025 n=1,060
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    BI 456906; SURVODUTIDE
    2022-502442-27-00 17 countries 2024 n=2,042
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    BI 456906; SURVODUTIDE
    2022-502529-17-00 6 countries 2024 n=130
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    BI 456906; SURVODUTIDE
    2022-502531-18-00 11 countries 2024 n=248
    Ended
  • F. Hoffmann-La Roche AG Commercial
    N-[2-(3-CYANO-5-FLUOROPHENYL)-2-METHYL-1-OXOPROPYL]-BETA-ALANYL-L-ALPHA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALPHA-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-ALPHA-ASPARTYL-L-LYSYL-L-ISOLEUCYL-L-ALANYL-L-GLUTAMINYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL-2-[2-(2-AMINOETHOXY)ETHOXY]ACETYL-2-[2-(2-AMINOETHOXY)ETHOXY]ACETYL]-L-LYSYL-L-ALANYL-L-PHENYLALANYL-L-VALYL-L-GLUTAMINYL-L-TRYPTOPHYL-L-LEUCYL-L-ISOLEUCYL-L-ALANYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-L-SERINAMIDE
    2025-523104-71-00 9 countries 2026 n=754
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    N-[2-(3-CYANO-5-FLUOROPHENYL)-2-METHYL-1-OXOPROPYL]-BETA-ALANYL-L-ALPHA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALPHA-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-ALPHA-ASPARTYL-L-LYSYL-L-ISOLEUCYL-L-ALANYL-L-GLUTAMINYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL-2-[2-(2-AMINOETHOXY)ETHOXY]ACETYL-2-[2-(2-AMINOETHOXY)ETHOXY]ACETYL]-L-LYSYL-L-ALANYL-L-PHENYLALANYL-L-VALYL-L-GLUTAMINYL-L-TRYPTOPHYL-L-LEUCYL-L-ISOLEUCYL-L-ALANYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-L-SERINAMIDE
    2025-523106-32-00 8 countries 2026 n=551
    Recruiting
  • Kailera Therapeutics Inc. Commercial
    TYROSYL-2-AMINOISOBUTYRYL-GLUTAMYL-GLYCYL-THREONYL-PHENYLALANYLTHREONYL-SERYL-ASPARTATE-TYROSYL-SERYL-ISOLEUCYL-TYROSYL-LYSYL([2-[2- AMINOETHOXY]ETHOXY]ACETYL-[2-[2-AMINOETHOXY]ETHOXY]ACETYL-GAMMA-GLUTAMYL-EICOSANOYL)-GLUTAMYL-LYSYL-ISOLEUCYL-ALANYL-ALANYL-GLUTAMINE-GLUTAMYL-PHENYLALANYL-VALYL-ASPARAGINE-CHROMYL-LEUCYL-LEUCYL-ALANYL-GLYCYL-GLYCYL-PROLYL-SERYL-SERYL-GLYCYL-ALANYL-PROLYL-PROLYL-PROLYL-SERYL AMIDE
    2025-523486-17-00 6 countries n=612
    Pending
  • Kailera Therapeutics Inc. Commercial
    TYROSYL-2-AMINOISOBUTYRYL-GLUTAMYL-GLYCYL-THREONYL-PHENYLALANYLTHREONYL-SERYL-ASPARTATE-TYROSYL-SERYL-ISOLEUCYL-TYROSYL-LYSYL([2-[2- AMINOETHOXY]ETHOXY]ACETYL-[2-[2-AMINOETHOXY]ETHOXY]ACETYL-GAMMA-GLUTAMYL-EICOSANOYL)-GLUTAMYL-LYSYL-ISOLEUCYL-ALANYL-ALANYL-GLUTAMINE-GLUTAMYL-PHENYLALANYL-VALYL-ASPARAGINE-CHROMYL-LEUCYL-LEUCYL-ALANYL-GLYCYL-GLYCYL-PROLYL-SERYL-SERYL-GLYCYL-ALANYL-PROLYL-PROLYL-PROLYL-SERYL AMIDE
    2025-523510-87-00 6 countries n=626
    Pending
  • Kailera Therapeutics Inc. Commercial
    SEMAGLUTIDE; TYROSYL-2-AMINOISOBUTYRYL-GLUTAMYL-GLYCYL-THREONYL-PHENYLALANYLTHREONYL-SERYL-ASPARTATE-TYROSYL-SERYL-ISOLEUCYL-TYROSYL-LYSYL([2-[2- AMINOETHOXY]ETHOXY]ACETYL-[2-[2-AMINOETHOXY]ETHOXY]ACETYL-GAMMA-GLUTAMYL-EICOSANOYL)-GLUTAMYL-LYSYL-ISOLEUCYL-ALANYL-ALANYL-GLUTAMINE-GLUTAMYL-PHENYLALANYL-VALYL-ASPARAGINE-CHROMYL-LEUCYL-LEUCYL-ALANYL-GLYCYL-GLYCYL-PROLYL-SERYL-SERYL-GLYCYL-ALANYL-PROLYL-PROLYL-PROLYL-SERYL AMIDE
    2025-523511-11-00 2 countries n=268
    Pending
  • Metsera Inc. Commercial
    L-PHENYLALANYL-2-METHYLALANYL-L-ALFA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALFA-ASPARTYL-L-VALYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-LEUCYL-L-ALFA-GLUTAMYL-L-ALFA-GLUTAMYL-L-LYSYL-L-ARGINYL-L-VALYL-L-ARGINYL-L-ALFA-GLUTAMYL-L-PHENYLALANYL-L-ISOLEUCYL-L-ALFA-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-GLUTAMINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-PROLYL-L-PROLYLGLYCYL-L-LYSYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL]-L-LYSINE
    2025-523974-18-00 8 countries 2026 n=894
    Recruiting
  • Metsera Inc. Commercial
    L-PHENYLALANYL-2-METHYLALANYL-L-ALFA-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-ALFA-ASPARTYL-L-VALYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-LEUCYL-L-ALFA-GLUTAMYL-L-ALFA-GLUTAMYL-L-LYSYL-L-ARGINYL-L-VALYL-L-ARGINYL-L-ALFA-GLUTAMYL-L-PHENYLALANYL-L-ISOLEUCYL-L-ALFA-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-GLUTAMINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-PROLYL-L-PROLYLGLYCYL-L-LYSYL-N6-[N-(19-CARBOXY-1-OXONONADECYL)-L-GAMMA-GLUTAMYL]-L-LYSINE
    2025-523975-48-00 8 countries 2026 n=919
    Recruiting
  • Novo Nordisk A/S Commercial
    SEMAGLUTIDE
    2022-502922-41-00 6 countries 2023 n=86
    Ended
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-506929-11-00 10 countries 2022 n=1,101
    Ended
  • Novo Nordisk A/S Commercial
    LIRAGLUTIDE
    2023-508504-38-00 2 countries 2021 n=21
    Ended
  • Novo Nordisk A/S Commercial
    CAGRILINTIDE, SEMAGLUTIDE
    2023-509273-24-00 2 countries 2024 n=100
    Ended
  • Novo Nordisk A/S Commercial
    CAGRILINTIDE, SEMAGLUTIDE
    2024-512144-39-00 3 countries 2025 n=160
    Ended
  • Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali Academic
    ACETYLSALICYLIC ACID; CLOPIDOGREL; SEMAGLUTIDE
    2025-522486-29-01 1 country n=212
    Pending
  • Hospices Civils De Lyon Academic
    COLECALCIFEROL
    2023-507089-18-00 1 country 2023 n=68
    Recruiting
  • Institut Klinicke A Experimentalni Mediciny Academic
    IMP not specified
    2023-504988-16-00 1 country n=16
    Pending

Phase II

5 trials
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2023-510470-13-00 5 countries 2023 n=135
    Ended
  • F. Hoffmann-La Roche AG Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN LATENT MYOSTATIN; TIRZEPATIDE
    2024-519561-22-00 2 countries 2025 n=78
    Ended
  • Novo Nordisk A/S Commercial
    CAGRILINTIDE; CAGRILINTIDE, SEMAGLUTIDE; SEMAGLUTIDE
    2023-505857-42-00 6 countries 2024 n=308
    Ended
  • Pfizer Inc. Commercial
    LIRAGLUTIDE; PF-07976016-87
    2024-513679-42-00 2 countries 2025 n=53
    Ended
  • Region Hovedstaden Academic
    SEMAGLUTIDE
    2023-503753-35-01 1 country 2024 n=100
    Recruiting

Phase I/II

1 trial
  • AstraZeneca AB Commercial
    AZD6234; AZD9550
    2023-504215-32-00 3 countries 2023 n=108
    Ended

Phase IV

3 trials
  • Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre Academic
    DEXMEDETOMIDINE; KETAMINE HYDROCHLORIDE; MAGNESIUM SULFATE HEPTAHYDRATE
    2025-521047-20-00 1 country 2025 n=64
    Halted
  • Region Midtjylland Academic
    SEMAGLUTIDE
    2023-506300-12-00 1 country 2023 n=24
    Ended
  • Rijnstate Ziekenhuis Stichting Academic
    SEMAGLUTIDE
    2022-501392-81-00 1 country 2024 n=280
    Ended

Phase I

3 trials
  • Camurus AB Commercial
    IMP not specified
    2024-518040-21-00 1 country 2024 n=80
    Ended
  • Corteria Pharmaceuticals Commercial
    IMP not specified
    2024-514853-31-00 1 country 2024 n=112
    Recruiting
  • Resalis Therapeutics S.r.l. Commercial
    IMP not specified
    2024-514871-17-00 1 country 2024 n=80
    Ended

Phase I (Other)

19 trials
  • Boehringer Ingelheim International GmbH Commercial
    IMP not specified
    2023-506233-30-01 1 country 2024 n=24
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-519277-18-00 1 country 2025 n=40
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-519296-25-00 1 country n=100
    Pending
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-521401-41-00 1 country n=30
    Pending
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-522766-78-00 1 country 2025 n=16
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-524052-58-00 1 country 2026 n=60
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-524210-28-00 1 country 2026 n=10
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-524856-73-00 1 country 2026 n=26
    Recruiting
  • Genentech Inc. Commercial
    IMP not specified
    2025-521888-13-00 1 country 2025 n=72
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2025-521921-34-00 1 country 2025 n=32
    Ended
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-504782-23-00 1 country 2024 n=150
    Ended
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-504792-24-00 1 country 2024 n=60
    Ended
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-509961-19-00 1 country 2024 n=42
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-513863-21-00 1 country n=16
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-518535-11-00 1 country 2025 n=8
    Ended
  • Rose Pharma Inc. Commercial
    IMP not specified
    2023-507758-34-00 1 country 2023 n=12
    Ended
  • Zealand Pharma A/S Commercial
    IMP not specified
    2024-518124-77-00 1 country 2025 n=48
    Ended
  • Zealand Pharma A/S Commercial
    IMP not specified
    2025-520598-38-00 1 country 2025 n=48
    Ended
  • Pauls Stradins Clinical University Hospital Academic
    IMP not specified
    2024-510885-17-01 1 country 2025 n=10
    Ended

Other

1 trial
  • Empros Pharma AB Commercial
    ACARBOSE, ORLISTAT; ORLISTAT
    2023-505671-74-00 1 country 2023 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 10 Phase I (Other), Phase II, Phase III 5
Novo Nordisk A/S Commercial 9 Phase I (Other), Phase II, Phase III 0
Boehringer Ingelheim International GmbH Commercial 4 Phase I (Other), Phase III 0
Pfizer Inc. Commercial 3 Phase I (Other), Phase II 0
Amgen Inc. Commercial 3 Phase II, Phase III 0
Kailera Therapeutics Inc. Commercial 3 Phase III 0
Genentech Inc. Commercial 2 Phase I (Other) 0
Zealand Pharma A/S Commercial 2 Phase I (Other) 0
Metsera Inc. Commercial 2 Phase III 2
Camurus AB Commercial 1 Phase I 0
Corteria Pharmaceuticals Commercial 1 Phase I 1
Resalis Therapeutics S.r.l. Commercial 1 Phase I 0
Empros Pharma AB Commercial 1 Other 0
Rose Pharma Inc. Commercial 1 Phase I (Other) 0
AstraZeneca AB Commercial 1 Phase I/II 0
Pauls Stradins Clinical University Hospital Academic 1 Phase I (Other) 0
Region Hovedstaden Academic 1 Phase II 1
Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali Academic 1 Phase III 0
Hospices Civils De Lyon Academic 1 Phase III 1
Institut Klinicke A Experimentalni Mediciny Academic 1 Phase III 0
New trials by year
2021
1
2022
1
2023
7
2024
14
2025
14
2026
7
← All indication landscapes